Ovarian Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016 - GlobalData

Ovarian Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

Ovarian Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016 - GlobalData
Ovarian Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016
Published Sep 14, 2016
237 pages — Published Sep 14, 2016
Price US$ 4,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GlobalData's Medical Devices sector report, Ovarian Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016' provides an overview of Ovarian Cancer Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Ovarian Cancer Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Ovarian Cancer Diagnostic Tests under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Ovarian Cancer Diagnostic Tests and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Ovarian Cancer Diagnostic Tests under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the products current stage of development, territory and estimated launch date

  
Source:
Document ID
GDME0222EPD
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
1 Table of Contents215
  1.1 List of Tables97
  1.2 List of Figures161
2 Introduction171
  2.1 Ovarian Cancer Diagnostic Tests Overview171
3 Products under Development185
  3.1 Ovarian Cancer Diagnostic Tests - Pipeline Products by Stage of Development181
  3.2 Ovarian Cancer Diagnostic Tests - Pipeline Products by Territory191
  3.3 Ovarian Cancer Diagnostic Tests - Pipeline Products by Regulatory Path201
  3.4 Ovarian Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date211
  3.5 Ovarian Cancer Diagnostic Tests - Ongoing Clinical Trials221
4 Ovarian Cancer Diagnostic Tests - Pipeline Products under Development by Companies238
  4.1 Ovarian Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development234
  4.2 Ovarian Cancer Diagnostic Tests - Pipeline Products by Stage of Development274
5 Ovarian Cancer Diagnostic Tests Companies and Product Overview31116
  5.1 A&G Pharmaceutical, Inc. Company Overview311
    5.1.1 A&G Pharmaceutical, Inc. Pipeline Products &Ongoing Clinical Trials Overview312
  5.2 Abnova Corporation Company Overview331
    5.2.1 Abnova Corporation Pipeline Products &Ongoing Clinical Trials Overview332
  5.3 Almac Diagnostics Limited Company Overview351
    5.3.1 Almac Diagnostics Limited Pipeline Products &Ongoing Clinical Trials Overview351
  5.4 ANGLE plc Company Overview361
    5.4.1 ANGLE plc Pipeline Products &Ongoing Clinical Trials Overview363
  5.5 AroCell AB Company Overview391
    5.5.1 AroCell AB Pipeline Products &Ongoing Clinical Trials Overview391
  5.6 ArtemixRx Company Overview401
    5.6.1 ArtemixRx Pipeline Products &Ongoing Clinical Trials Overview401
  5.7 Augusta University Company Overview411
    5.7.1 Augusta University Pipeline Products &Ongoing Clinical Trials Overview411
  5.8 Aurelium BioPharma Inc. Company Overview421
    5.8.1 Aurelium BioPharma Inc. Pipeline Products &Ongoing Clinical Trials Overview423
  5.9 Avant Diagnostics, Inc. Company Overview451
    5.9.1 Avant Diagnostics, Inc. Pipeline Products &Ongoing Clinical Trials Overview451
  5.10 Axela Inc. Company Overview461
    5.10.1 Axela Inc. Pipeline Products &Ongoing Clinical Trials Overview461
  5.11 Ayanda Biosystems S.A. Company Overview471
    5.11.1 Ayanda Biosystems S.A. Pipeline Products &Ongoing Clinical Trials Overview471
  5.12 Becton, Dickinson and Company Company Overview481
    5.12.1 Becton, Dickinson and Company Pipeline Products &Ongoing Clinical Trials Overview482
  5.13 Bioindustry Park Silvano Fumero S.p.A. Company Overview501
    5.13.1 Bioindustry Park Silvano Fumero S.p.A. Pipeline Products &Ongoing Clinical Trials Overview501
  5.14 Ceres Nanosciences, Inc. Company Overview511
    5.14.1 Ceres Nanosciences, Inc. Pipeline Products &Ongoing Clinical Trials Overview512
  5.15 Chronix Biomedical, Inc. Company Overview531
    5.15.1 Chronix Biomedical, Inc. Pipeline Products &Ongoing Clinical Trials Overview531
  5.16 Clarient, Inc. Company Overview541
    5.16.1 Clarient, Inc. Pipeline Products &Ongoing Clinical Trials Overview541
  5.17 ClavGen Therapeutics LLC Company Overview551
    5.17.1 ClavGen Therapeutics LLC Pipeline Products &Ongoing Clinical Trials Overview551
  5.18 Cleveland Diagnostics Inc. Company Overview561
    5.18.1 Cleveland Diagnostics Inc. Pipeline Products &Ongoing Clinical Trials Overview561
  5.19 Clovis Oncology, Inc. Company Overview571
    5.19.1 Clovis Oncology, Inc. Pipeline Products &Ongoing Clinical Trials Overview571
  5.20 Courtagen Life Sciences, Inc. Company Overview581
    5.20.1 Courtagen Life Sciences, Inc. Pipeline Products &Ongoing Clinical Trials Overview581
  5.21 Dako A/S Company Overview591
    5.21.1 Dako A/S Pipeline Products &Ongoing Clinical Trials Overview591
  5.22 Dana-Farber Cancer Institute, Inc. Company Overview601
    5.22.1 Dana-Farber Cancer Institute, Inc. Pipeline Products &Ongoing Clinical Trials Overview601
  5.23 Diazyme Laboratories Company Overview611
    5.23.1 Diazyme Laboratories Pipeline Products &Ongoing Clinical Trials Overview614
  5.24 Eventus Diagnostics, Inc. Company Overview651
    5.24.1 Eventus Diagnostics, Inc. Pipeline Products &Ongoing Clinical Trials Overview651
  5.25 Exiqon A/S Company Overview661
    5.25.1 Exiqon A/S Pipeline Products &Ongoing Clinical Trials Overview661
  5.26 Exosomics Siena SpA Company Overview671
    5.26.1 Exosomics Siena SpA Pipeline Products &Ongoing Clinical Trials Overview671
  5.27 Fahy Gurteen UK Limited Company Overview681
    5.27.1 Fahy Gurteen UK Limited Pipeline Products &Ongoing Clinical Trials Overview681
  5.28 Foundation Medicine, Inc. Company Overview691
    5.28.1 Foundation Medicine, Inc. Pipeline Products &Ongoing Clinical Trials Overview692
  5.29 French National Institute of Health and Medical Research Company Overview711
    5.29.1 French National Institute of Health and Medical Research Pipeline Products &Ongoing Clinical Trials Overview711
  5.30 Ganymed Pharmaceuticals AG Company Overview721
    5.30.1 Ganymed Pharmaceuticals AG Pipeline Products &Ongoing Clinical Trials Overview721
  5.31 GeneNews Limited Company Overview731
    5.31.1 GeneNews Limited Pipeline Products &Ongoing Clinical Trials Overview732
  5.32 Georgia Institute of Technology Company Overview751
    5.32.1 Georgia Institute of Technology Pipeline Products &Ongoing Clinical Trials Overview751
  5.33 GlycoZym Company Overview761
    5.33.1 GlycoZym Pipeline Products &Ongoing Clinical Trials Overview761
  5.34 H. Lee Moffitt Cancer Center &Research Institute, Inc. Company Overview771
    5.34.1 H. Lee Moffitt Cancer Center &Research Institute, Inc. Pipeline Products &Ongoing Clinical Trials Overview771
  5.35 Ikonisys, Inc. Company Overview781
    5.35.1 Ikonisys, Inc. Pipeline Products &Ongoing Clinical Trials Overview781
  5.36 Inanovate (UK) Ltd. Company Overview791
    5.36.1 Inanovate (UK) Ltd. Pipeline Products &Ongoing Clinical Trials Overview791
  5.37 InterGenetics Incorporated Company Overview801
    5.37.1 InterGenetics Incorporated Pipeline Products &Ongoing Clinical Trials Overview801
  5.38 IV Diagnostics, Inc. Company Overview811
    5.38.1 IV Diagnostics, Inc. Pipeline Products &Ongoing Clinical Trials Overview811
  5.39 John Hopkins University Company Overview821
    5.39.1 John Hopkins University Pipeline Products &Ongoing Clinical Trials Overview823
  5.40 KIYATEC Inc. Company Overview851
    5.40.1 KIYATEC Inc. Pipeline Products &Ongoing Clinical Trials Overview851
  5.41 Lab Discoveries Ltd. Company Overview861
    5.41.1 Lab Discoveries Ltd. Pipeline Products &Ongoing Clinical Trials Overview861
  5.42 Laboratorios SALVAT S.A. Company Overview871
    5.42.1 Laboratorios SALVAT S.A. Pipeline Products &Ongoing Clinical Trials Overview871
  5.43 Laboratory Corporation of America Holdings Company Overview881
    5.43.1 Laboratory Corporation of America Holdings Pipeline Products &Ongoing Clinical Trials Overview882
  5.44 Louisville Bioscience, Inc. Company Overview901
    5.44.1 Louisville Bioscience, Inc. Pipeline Products &Ongoing Clinical Trials Overview901
  5.45 MabCure Inc. Company Overview911
    5.45.1 MabCure Inc. Pipeline Products &Ongoing Clinical Trials Overview912
  5.46 MDNA Life Sciences, Inc. Company Overview931
    5.46.1 MDNA Life Sciences, Inc. Pipeline Products &Ongoing Clinical Trials Overview932
  5.47 MDxHealth SA Company Overview951
    5.47.1 MDxHealth SA Pipeline Products &Ongoing Clinical Trials Overview952
  5.48 Metabolon, Inc. Company Overview971
    5.48.1 Metabolon, Inc. Pipeline Products &Ongoing Clinical Trials Overview971
  5.49 Milagen, Inc. Company Overview981
    5.49.1 Milagen, Inc. Pipeline Products &Ongoing Clinical Trials Overview981
  5.50 Myriad Genetics, Inc. Company Overview991
    5.50.1 Myriad Genetics, Inc. Pipeline Products &Ongoing Clinical Trials Overview992
  5.51 Nanosphere, Inc. Company Overview1011
    5.51.1 Nanosphere, Inc. Pipeline Products &Ongoing Clinical Trials Overview1012
  5.52 National University of Singapore Company Overview1031
    5.52.1 National University of Singapore Pipeline Products &Ongoing Clinical Trials Overview1031
  5.53 Novel Bio-spectrum Technologies, Inc. Company Overview1041
    5.53.1 Novel Bio-spectrum Technologies, Inc. Pipeline Products &Ongoing Clinical Trials Overview1041
  5.54 Olympia Diagnostics, Inc Company Overview1051
    5.54.1 Olympia Diagnostics, Inc Pipeline Products &Ongoing Clinical Trials Overview1051
  5.55 Oncgnostics GmbH Company Overview1061
    5.55.1 Oncgnostics GmbH Pipeline Products &Ongoing Clinical Trials Overview1061
  5.56 Oncimmune (USA) LLC Company Overview1071
    5.56.1 Oncimmune (USA) LLC Pipeline Products &Ongoing Clinical Trials Overview1071
  5.57 Orion Genomics LLC Company Overview1081
    5.57.1 Orion Genomics LLC Pipeline Products &Ongoing Clinical Trials Overview1081
  5.58 Oryzon Genomics SA Company Overview1091
    5.58.1 Oryzon Genomics SA Pipeline Products &Ongoing Clinical Trials Overview1091
  5.59 OTraces Inc. Company Overview1101
    5.59.1 OTraces Inc. Pipeline Products &Ongoing Clinical Trials Overview1102
  5.60 PeriRx LLC Company Overview1121
    5.60.1 PeriRx LLC Pipeline Products &Ongoing Clinical Trials Overview1121
  5.61 Phenomenome Discoveries, Inc. Company Overview1131
    5.61.1 Phenomenome Discoveries, Inc. Pipeline Products &Ongoing Clinical Trials Overview1131
  5.62 Precision Biologics, Inc. Company Overview1141
    5.62.1 Precision Biologics, Inc. Pipeline Products &Ongoing Clinical Trials Overview1141
  5.63 Pronota NV Company Overview1151
    5.63.1 Pronota NV Pipeline Products &Ongoing Clinical Trials Overview1151
  5.64 Protagen AG Company Overview1161
    5.64.1 Protagen AG Pipeline Products &Ongoing Clinical Trials Overview1161
  5.65 Proteomika Company Overview1171
    5.65.1 Proteomika Pipeline Products &Ongoing Clinical Trials Overview1171
  5.66 Provista Diagnostics Inc. Company Overview1181
    5.66.1 Provista Diagnostics Inc. Pipeline Products &Ongoing Clinical Trials Overview1181
  5.67 RiboMed Biotechnologies, Inc. Company Overview1191
    5.67.1 RiboMed Biotechnologies, Inc. Pipeline Products &Ongoing Clinical Trials Overview1191
  5.68 Roche Diagnostics International Ltd. Company Overview1201
    5.68.1 Roche Diagnostics International Ltd. Pipeline Products &Ongoing Clinical Trials Overview1202
  5.69 Rosetta Genomics Ltd Company Overview1221
    5.69.1 Rosetta Genomics Ltd Pipeline Products &Ongoing Clinical Trials Overview1222
  5.70 SomaLogic, Inc. Company Overview1241
    5.70.1 SomaLogic, Inc. Pipeline Products &Ongoing Clinical Trials Overview1242
  5.71 Soricimed Biopharma Inc. Company Overview1261
    5.71.1 Soricimed Biopharma Inc. Pipeline Products &Ongoing Clinical Trials Overview1262
  5.72 Stage I Diagnostics, Inc. Company Overview1281
    5.72.1 Stage I Diagnostics, Inc. Pipeline Products &Ongoing Clinical Trials Overview1281
  5.73 SurExam Life Science &Technology Co. Company Overview1291
    5.73.1 SurExam Life Science &Technology Co. Pipeline Products &Ongoing Clinical Trials Overview1291
  5.74 Target Discovery, Inc. Company Overview1301
    5.74.1 Target Discovery, Inc. Pipeline Products &Ongoing Clinical Trials Overview1301
  5.75 Teva Pharmaceutical Industries Ltd. Company Overview1311
    5.75.1 Teva Pharmaceutical Industries Ltd. Pipeline Products &Ongoing Clinical Trials Overview1312
  5.76 The University of Adelaide Company Overview1331
    5.76.1 The University of Adelaide Pipeline Products &Ongoing Clinical Trials Overview1331
  5.77 The University of Texas MD Anderson Cancer Center Company Overview1341
    5.77.1 The University of Texas MD Anderson Cancer Center Pipeline Products &Ongoing Clinical Trials Overview1341
  5.78 Todos Medical Company Overview1351
    5.78.1 Todos Medical Pipeline Products &Ongoing Clinical Trials Overview1351
  5.79 Transbiomed, SL Company Overview1361
    5.79.1 Transbiomed, SL Pipeline Products &Ongoing Clinical Trials Overview1361
  5.80 Universite de Montreal Company Overview1371
    5.80.1 Universite de Montreal Pipeline Products &Ongoing Clinical Trials Overview1371
  5.81 University of South Florida Company Overview1381
    5.81.1 University of South Florida Pipeline Products &Ongoing Clinical Trials Overview1382
  5.82 US Biomarkers, Inc. Company Overview1401
    5.82.1 US Biomarkers, Inc. Pipeline Products &Ongoing Clinical Trials Overview1401
  5.83 Vermillion, Inc. Company Overview1411
    5.83.1 Vermillion, Inc. Pipeline Products &Ongoing Clinical Trials Overview1412
  5.84 Vitatex Inc. Company Overview1431
    5.84.1 Vitatex Inc. Pipeline Products &Ongoing Clinical Trials Overview1432
  5.85 Vitruvian Biomedical, Inc. Company Overview1451
    5.85.1 Vitruvian Biomedical, Inc. Pipeline Products &Ongoing Clinical Trials Overview1451
  5.86 Yale University Company Overview1461
    5.86.1 Yale University Pipeline Products &Ongoing Clinical Trials Overview1461
6 Ovarian Cancer Diagnostic Tests - Recent Developments14787
  6.1 Aug 18, 2016: MDxHealth Reports Second Quarter and First Half 2016 Results1472
  6.2 Aug 11, 2016: Metabolon Raises USD15 Million in Venture Financing1491
  6.3 Aug 11, 2016: GeneNews Announces Q2-2016 Financial Results1491
  6.4 Aug 10, 2016: Vermillion Reports Second Quarter 2016 Results1491
  6.5 Aug 09, 2016: Myriad Genetics Reports Fiscal Fourth-Quarter 2016 Financial Results1502
  6.6 Aug 08, 2016: Oryzon Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 20161521
  6.7 Aug 08, 2016: Clovis Oncology Announces Q2 2016 Operating Results and Corporate Update1532
  6.8 Aug 04, 2016: Teva Reports Second Quarter 2016 Results1554
  6.9 Aug 04, 2016: BD Announces Results For 2016 Third Fiscal Quarter1592
  6.10 Aug 04, 2016: Tesaro Announces Second-Quarter 2016 Operating Results1612
  6.11 Aug 02, 2016: ASPiRA LABS Expands Coverage for OVA1 in California1631
  6.12 Aug 02, 2016: Pfizer Reports Second-Quarter 2016 Results1634
  6.13 Aug 02, 2016: Foundation Medicine Announces 2016 Second Quarter Results and Recent Highlights1672
  6.14 Jul 28, 2016: BD Names R. Andrew Eckert To Board Of Directors1691
  6.15 Jul 27, 2016: Angle Announces Initiation Of 200 Patient United States Ovarian Cancer Study1691
  6.16 Jul 27, 2016: ASPiRA LABS Expands Coverage for OVA1 in Texas1701
  6.17 Jul 27, 2016: Laboratory Corporation of America Holdings Announces 2016 Second Quarter Results and Raises 2016 Guidance1712
  6.18 Jul 21, 2016: Teva Pharma Raises USD304 Million in Public Offering of 0.125% Notes Due 20181731
  6.19 Jul 21, 2016: Teva Pharma Raises USD354.6 Million in Public Offering of 1% Notes Due 20251741
  6.20 Jul 21, 2016: Teva Pharma Raises USD354.6 Million in Public Offering of 0.5% Notes Due 20221741
  6.21 Jul 20, 2016: Abbott Reports Second-Quarter 2016 Results1752
  6.22 Jul 20, 2016: Protagen Appoints Bernhard Kirschbaum as New Chairman and Oliver Schacht as New Board Member1771
  6.23 Jul 19, 2016: Angle Announces Initiation Of Two Hundred Patient European Ovarian Cancer Study1781
  6.24 Jul 19, 2016: ASPiRA LABS Announces Strategic Michigan Coverage for OVA11791
  6.25 Jul 19, 2016: Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects1796
  6.26 Jul 18, 2016: Teva Pharma Raises USD3.5 Billion in Public Offering of 3.15% Notes Due 20261851
  6.27 Jul 18, 2016: Teva Pharma Raises USD1.5 Billion in Public Offering of 1.4% Notes Due 20181861
  6.28 Jul 18, 2016: Teva Pharma Raises USD3 Billion in Public Offering of 2.2% Notes Due 20211861
  6.29 Jul 18, 2016: Teva Pharma Raises USD3 Billion in Public Offering of 2.8% Notes Due 20231871
  6.30 Jul 18, 2016: Teva Pharma Raises USD2 Billion in Public Offering of 4.1% Notes Due 20461871
  6.31 Jul 18, 2016: Teva Pharma Raises USD2 Billion in Public Offering of 1.7% Notes Due 20191881
  6.32 Jul 15, 2016: PhRMA Welcomes Five New Member Companies1881
  6.33 Jul 13, 2016: Nasdaq Copenhagen accepts Exiqon request for delisting and cancellation from trading of the Exiqon shares1891
  6.34 Jul 13, 2016: Simplifying access to gene testing for women with ovarian cancer improves treatment choices and could save lives1892
  6.35 Jul 13, 2016: Pfizer and NovaMedica announce a strategic partnership in Russia1911
  6.36 Jul 11, 2016: Rosetta Genomics Receives U.S. Patent Allowance for microRNA-based Ovarian Cancer Treatment1921
  6.37 Jul 04, 2016: Oncimmune Enters into Research Agreement with Egybiotech and Aarhus University Hospital1921
  6.38 Jul 04, 2016: Exiqon Nomination of candidates for the supervisory board1931
  6.39 Jun 30, 2016: Tesaro Raises USD433.2 Million in Public Offering of Shares1931
  6.40 Jun 30, 2016: Tesaro to Raise up to USD55.8 Million in Public Offering of Shares1931
  6.41 Jun 29, 2016: Myriad's myChoice HRD Test Successfully Identifies Patients that Meet Primary Endpoint in TESARO's Pivotal Phase 3 Ovarian Cancer Study with Niraparib1931
  6.42 Jun 23, 2016: Oncimmune Appoints Julian Hirst as Non-Executive Director1941
  6.43 Jun 16, 2016: Pfizer Breaks Ground On New Biologics Clinical Manufacturing Facility In Andover, Massachusetts1951
  6.44 Jun 15, 2016: GeneNews Announces Filing of Q1-2016 Financial Results1951
  6.45 Jun 10, 2016: Diadexus to File Chapter 71961
  6.46 Jun 04, 2016: T-Cell Receptor Sequencing Reveals Novel Biomarkers for Ovarian Cancer1971
  6.47 May 31, 2016: Pfizer Raises USD1.25 Billion in Public Offering of 1.2% Notes Due 20181971
  6.48 May 31, 2016: Pfizer Raises USD0.85 Billion in Public Offering of 1.45% Notes Due 20191981
  6.49 May 31, 2016: Pfizer Raises USD1.15 Billion in Public Offering of 1.95% Notes Due 20211981
  6.50 May 31, 2016: Pfizer Raises USD1.25 Billion in Public Offering of 2.75% Notes Due 20261991
  6.51 May 31, 2016: Pfizer Raises USD0.5 Billion in Public Offering of 4.4% Notes Due 20441991
  6.52 May 27, 2016: GeneNews Announces Full Year 2015 Financial Results2001
  6.53 May 25, 2016: Stage I Diagnostics Raises USD0.1 Million in Venture Financing2011
  6.54 May 25, 2016: Novartis highlights its strong foundation for long-term, sustainable growth at the third Meet Novartis Management event2012
  6.55 May 24, 2016: COTA Increases Cross-Industry Support With the Addition of Celgene, Foundation Medicine HealthScape Advisors and Novartis as Strategic Investors2031
  6.56 May 19, 2016: GeneNews Announces a Further Extension of the TSX s Remedial Review Process2031
  6.57 May 17, 2016: Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of Novartis2041
  6.58 May 16, 2016: Vermillion to Showcase Comparison of Overa and ROMA Algorithms at ACOG 2016 Annual Meeting2041
  6.59 May 16, 2016: Nanosphere Announces First Quarter Results2051
  6.60 May 16, 2016: Vermillion Reports First Quarter 2016 Results2061
  6.61 May 16, 2016: Vermillion Reports Fourth Quarter and Full Year 2015 Results2071
  6.62 May 15, 2016: Luminex Acquires Nanosphere in Tender Offer2081

Table Of Contents

GlobalData—GlobalData uses proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries.

About the Author


Cite this Report

  
MLA:
GlobalData. "Ovarian Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016" Sep 14, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GlobalData/Ovarian-Cancer-Diagnostic-Tests-Medical-Devices-Pipeline-Assessment-2016-2085-23613>
  
APA:
GlobalData. (2016). Ovarian Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016 Sep 14, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GlobalData/Ovarian-Cancer-Diagnostic-Tests-Medical-Devices-Pipeline-Assessment-2016-2085-23613>
  
US$ 4,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.